CODX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CO

Mkt Cap

$4.5M

Volume

327.51K

Next Earnings

November 12th

Loading chart

CO

CODXCo-Diagnostics, Inc. Common Stock

CODX

Pay with—

Available Balance0.00

CO

Mkt Cap

$4.6M

Volume

327.51K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Is Co-Diagnostics National Security’s Next Diagnostic Pick?Following the WHO's declaration of a Public Health Emergency for the Bundibugyo virus Ebola outbreak on May 17, 2026, biodefense diagnostics companies are experiencing significant capital inflows. Co-Diagnostics is positioned as a strategic play due to its decentralized manufacturing network through joint ventures in India (CoSara) and Saudi Arabia (CoMira), which addresses national security demands for localized production. The company is advancing PCR assays for Ebola detection and has near-term catalysts including FDA 510(k) submission and India TB test commercialization in Q3 2026, though the stock's recent 200%+ surge on low float presents both opportunity and volatility.Investing.com · May 28, 2026

Co-Diagnostics Reports Full Year 2025 Financial ResultsCo-Diagnostics (NASDAQ: CODX) reported full year 2025 results with revenue of $0.6 million versus $3.9 million in 2024, primarily due to lower grant revenue. The company posted a net loss of $46.9 million ($35.25 per share) compared to $37.6 million in 2024, driven by an $18.9 million non-cash impairment charge on intangible assets. Cash reserves declined to $11.9 million from $29.7 million. However, the company advanced its global commercialization strategy through CoSara and CoMira joint ventures, progressed clinical pipeline programs, and expanded AI capabilities.Benzinga · Mar 31, 2026

Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health OrganizationCo-Diagnostics (NASDAQ: CODX) has shipped PCR Pro instruments and TB test kits to its joint venture CoSara Diagnostics in India to begin clinical performance studies. The company's PCR platform and TB test design align with new WHO recommendations for near-point-of-care molecular testing using tongue swab samples, positioning Co-Dx favorably for regulatory submissions in India.Benzinga · Mar 25, 2026

Co-Diagnostics Announces Reverse Stock SplitCo-Diagnostics Inc. (NASDAQ: CODX) announced a 1-for-30 reverse stock split effective January 2, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split was approved by stockholders on December 5, 2025, and the stock will continue trading under the symbol 'CODX' on a split-adjusted basis.Benzinga · Dec 30, 2025

Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, IndiaCo-Diagnostics' joint venture CoSara will participate in VIROCON 2025, presenting ongoing preclinical studies for tuberculosis and HPV tests on their PCR point-of-care platform, with promising early results supporting advancement to clinical performance testing.Benzinga · Dec 8, 2025

Co-Diagnostics Executive Leadership Team to Attend Global Health Exhibition 2025 in Riyadh, Saudi ArabiaCo-Diagnostics will attend the Global Health Exhibition 2025 in Riyadh, showcasing their upcoming PCR point-of-care platform and exploring a potential joint venture in the Middle East and North Africa region.Benzinga · Oct 22, 2025

Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesCo-Diagnostics, Inc. closed a registered direct offering of 9,619,000 common stock shares at $0.40 per share, raising approximately $3.8 million for working capital and general corporate purposes.Benzinga · Sep 18, 2025

Co-Diagnostics Sales Plunge 93 PercentCo-Diagnostics reported a Q2 2025 GAAP EPS loss of $0.23, slightly improving from the prior year. Revenue fell sharply to $0.2 million from $2.7 million in Q2 2024, with the company still in a pre-commercial phase focused on developing infectious disease diagnostic platforms.The Motley Fool · Aug 14, 2025

Infectious Disease Diagnostics Market to Reach USD 43.09 Billion by 2031 | SkyQuest TechnologyThe global infectious disease diagnostics market is projected to reach $43.09 billion by 2031, growing at a CAGR of 8.20% during the forecast period. The market is driven by advancements in diagnostic technologies, rising cases of infectious diseases, and increased R&D funding.Benzinga · Oct 24, 2024

Elevance Health (ELV) Beats Q1 Earnings EstimatesElevance Health (ELV) delivered earnings and revenue surprises of 0.95% and 0.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · Apr 18, 2024

to start trading

CO

CODXCo-Diagnostics, Inc. Common Stock

CODX

Pay with—

Available Balance0.00

Your PositionYou don't own any CODX yet.

Related Tickers

Earnings